ECM1 and acute kidney injury: By inhibiting ECM1 and activating the GM-CSF/STAT5/Arg1 pathway to promote alternative macrophage M2, Shionone reduces the inflammatory response to accelerate tissue repair and is able to attenuate AKI in vitro and in vivo.